VIA
ABMD

Vantage Investment Advisors’s Abiomed Inc ABMD Stock Holding History

Vantage Investment Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$27K Hold
60
– – 0.01% 375
2018
Q2 		$25K Hold
60
– – 0.01% 376
2018
Q1 		$17K Hold
60
– – ﹤0.01% 459
2017
Q4 		$11K Buy
+60
New +$11.2K ﹤0.01% 574

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vantage Investment Advisors's ABMD Position: Q3 2018 in Review

Vantage Investment Advisors held its Abiomed Inc (ABMD) position steady in Q3 2018 at 60 shares worth $27K. The position accounts for 0.01% of the portfolio, ranked #375.

Vantage Investment Advisors first reported a position in ABMD in Q4 2017 and has held it in 4 quarters since. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

  • Vantage Investment Advisors held 60 shares of Abiomed Inc worth $27K as of Q3 2018.
  • Vantage Investment Advisors left its Abiomed Inc share count unchanged in Q3 2018.
  • Abiomed Inc made up 0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #375 holding.
  • Vantage Investment Advisors first reported a position in Abiomed Inc in Q4 2017 and has held it in 4 quarters since.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.